Shaping Treatment Expectation to Optimize Efficacy of Interleukin 17A Antagonist Secukinumab in Psoriasis Patients
This study demonstrates an attempt to modify patients' treatment expectations to enhance the effectiveness of pharmacological therapy with secukinumab in psoriasis patients. However, verbal suggestion alone did not significantly improve clinical outcomes, suggesting that future studies should explore alternative approaches to leverage placebo effects to the benefit of patients with psoriasis.
Authors
- Manfred Schedlowski (ORCID: https://orcid.org/0000-0002-9968-9770)
- Frederik Krefting (ORCID: https://orcid.org/0000-0002-6164-3726)
- Wiebke Sondermann (ORCID: https://orcid.org/0000-0002-3684-3523)
- Senta Mühlhaus
- Stefanie Hölsken (ORCID: https://orcid.org/0000-0001-6756-6963)
- Daniela Bese
Institutions
- Karolinska Institutet (SE)
- University of Duisburg-Essen (DE)
Publication Details
- Journal
- Psoriasis Targets and Therapy
- Published
- 2025-01-01
- DOI
- https://doi.org/10.2147/ptt.s486338
- Citations
- 1
- Primary Topic
- Pain Management and Placebo Effect
- Type
- article
- Field-Weighted Citation Impact
- 1.43
Funders
- Deutsche Forschungsgemeinschaft